Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Clinical Study of Ultra-transplantation for the Treatment of Major Thalassemia Scheme
Sponsor: Hu Peng
Summary
Yunnan is a high-incidence area of Eastern Mediterranean (thalassemia) in China, and the treatment cost of thalassemia patients is high, hematopoietic stem cell transplantation (HSCT) is the only means to cure thalassemia, but there are problems in donor screening and the risk of complications. Professor Ai Huisheng's team proposed a new concept of hypertransplantation, which does not require pretreatment and has no risk of GVHD, and animal experiments have shown good efficacy. Under the guidance of Professor Ai, the center plans to carry out clinical research on hypertransplantation and explore safe and effective new therapies for thalassemia.
Official title: Clinical Study Protocol for Ultra-transplantation for the Treatment of Eastern Mediterranean Major
Key Details
Gender
All
Age Range
7 Years - 12 Years
Study Type
INTERVENTIONAL
Enrollment
5
Start Date
2025-08-29
Completion Date
2026-12-31
Last Updated
2025-09-02
Healthy Volunteers
No
Conditions
Interventions
Supergraft
This study is a prospective, single-center, single-arm clinical study, and it is planned to include 3-5 patients with Eastern Mediterranean major who have no HSCT indication and cannot undergo Eastern Mediterranean gene therapy. The diagnosis of Eastern Mediterranean major was determined by the genotype of Eastern Mediterranean and the clinical manifestations of patients, and patients who met the inclusion criteria were screened and enrolled and received super transplant therapy.
Locations (1)
Yunnan First People's Hospital
Kunming, Yunnan, China